Evidence map›Paper›PMID 42060159›Full record

ArticleAdvances in therapy2026

Association Between Socioeconomic Indicators and Growth Hormone Treatment Patterns for Idiopathic Short Stature in China: A Large-Scale Real-World Study.

Chunxiu Gong, Xiaoping Luo, Ruimin Chen, Shengquan Cheng, Xinran Cheng, Hongwei Du, Wei Gu, Ke Huang, Xiaoyan Huang, Guimei Li and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Chunxiu Gong *Department of Endocrine and Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, 100045, China. chunxiugong@sina.com.
Xiaoping Luo *Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. xpluo@tjh.tjmu.edu.cn.ORCID http://orcid.org/0000-0002-3748-4817
Ruimin ChenDepartment of Endocrinology, Genetics and Metabolism, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, 350005, China.
Shengquan ChengDepartment of Pediatrics, First Affiliated Hospital of Air Force Medical University, Xi'an, 710032, China.
Xinran ChengDepartment of Pediatric Endocrine Genetics and Metabolism, Chengdu Women's and Children's Center Hospital, Chengdu, 610074, China.
Hongwei DuDepartment of Paediatrics, First Hospital of Jilin University, Changchun, 130021, China.
Wei GuDepartment of Endocrinology, Children's Hospital of Nanjing Medical University, Nanjing, 210008, China.
Ke HuangDepartment of Endocrinology, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310005, China.
Xiaoyan HuangDepartment of Genetics, Metabolism and Endocrinology, Hainan Women and Children's Medical Center, Haikou, 570312, China.
Guimei LiDepartment of Pediatrics, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Ping LiDepartment of Developmental Pediatrics, Second Hospital of Jilin University, Changchun, 130041, China.
Tang LiDepartment of Pediatric Endocrinology, Qingdao Women and Children's Hospital, Qingdao, 266000, China.
Li LiangDepartment of Pediatrics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Deyun LiuDepartment of Pediatrics, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
Shu LiuDepartment of Pediatric Endocrinology and Inherited Metabolic Diseases, Guangdong Women and Children Hospital, Guangzhou, 511442, China.
Yu LiuDepartment of Endocrine and Genetic Metabolism, Maternal and Child Health-Care Hospital in Guiyang, Guiyang, 550003, China.
Zhe SuDepartment of Endocrinology, Shenzhen Children's Hospital, No. 7019, Yitian Road, Shenzhen, 518038, China.
Yan SunDepartment of Pediatrics, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Chunlin WangDepartment of Pediatrics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Naijun WanDepartment of Pediatrics, Beijing Jishuitan Hospital, Beijing, 100035, China.
Haiying WuDepartment of Endocrinology, Metabolism, and Genetic Diseases, Children's Hospital of Soochow University, Suzhou, 215000, China.
Su WuDepartment of Endocrinology, Children's Hospital of Nanjing Medical University, Nanjing, 210008, China.
Wei WuDepartment of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Yu YangDepartment of Endocrinology and Genetics, Jiangxi Provincial Children's Hospital, Affiliated Children's Hospital of Nanchang University, Nanchang, 330006, China.
Hui YaoDepartment of Endocrinology and Metabolism, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430015, China.
Xiaoyong YuanDepartment of Endocrinology, Peking University First Hospital, Beijing, 100034, China.
Rongxiu ZhengDepartment of Pediatrics, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Min ZhuDepartment of Endocrinology, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecombinant human growth hormone (rhGH) treatment for idiopathic short stature (ISS) in China faces challenges including delayed initiation, poor persistence, limited adoption of advanced therapies, and conservative dosing. This study characterized real-world temporal and geographical patterns of rhGH therapy and identified associated socioeconomic factors.

methodsData from two nationwide registries comprising 24,384 children with ISS initiating rhGH were analyzed. Predictors of treatment effectiveness were identified via linear regression. Provincial variations and temporal trends were assessed via descriptive analysis and seasonal-trend decomposition. Spearman correlation was used to examine associations between treatment patterns and socioeconomic indicators.

resultsThe median rhGH initiation age was 8.45 years. Most patients (81.3%) initiated short-acting GH (SAGH; median dose 0.15 IU/kg/day), while 18.7% initiated long-acting GH (LAGH; median dose 0.20 mg/kg/week). Younger age and treatment duration ≥ 9 months predicted superior 1-year height standard deviation score gain (P < 0.001). Temporally, LAGH adoption and standard-dose regimens showed significant longitudinal increases (P < 0.05). Geographically, substantial variation existed in median initiation age (7.11-9.70 years), LAGH adoption rates (11.8-31.1%), and duration of therapy (DOT; 10.3-28.1 months). Higher per capita gross regional product correlated with younger initiation (ρ = - 0.530), higher LAGH adoption (ρ = 0.371), and longer DOT (ρ = 0.552). Conversely, higher rural population ratios correlated with delayed initiation, lower LAGH adoption, and shorter DOT (all P < 0.05).

conclusionGeographic heterogeneity in rhGH therapy is observed and correlates with regional socioeconomic profiles. To enhance therapeutic outcomes and support the balanced development of pediatric endocrine care, adaptive clinical management considering regional socioeconomic contexts is recommended.

Indexed as

Growth DisordersHuman Growth HormoneAdolescentBody HeightChildChild, PreschoolChinaFemaleHumansMaleRecombinant ProteinsRegistriesSocioeconomic FactorsHuman Growth HormoneRecombinant ProteinsGrowth hormoneIdiopathic short statureReal-world dataSocioeconomic factorsSpatial analysisTreatment pattern

Identifiers

PMID42060159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.